000			04208cam a2200385 i 4500
999			_c116410 _d116410
001			21433505
003			BJBSDDR
005			20230411090801.0
007			ta
008			200214t20202020nyuaf b 001 0 eng
010			_a 2019300476
020			_a9780525431992 _q(pbk)
040			_aDLC _beng _erda _cDLC _dDLC
042			_apcc
043			_an-us---
050	0	0	_aHD9995.H423 _bU627 2020
082	0	0	_a338.7/681761 _223
100			_aCarreyrou, Johr _eauthor. _923697
245	1	0	_aBad blood : _bsecrets and lies in a Silicon Valley Startup / _cJohn Carreyrou.
250			_aFirst Vintage Books Edition.
264		1	_aNew York : _bVintage Books, a division of Penguin Random House LLC, _c2020.
300			_a 341 pages, 8 unnumbered pages of plates : _bill ; _c21 cm
336			_atext _btxt _2rdacontent
337			_aunmediated _bn _2rdamedia
338			_avolume _bnc _2rdacarrier
504			_aIncludes bibliographical references (pages 307-326) and index.
520			_a"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- _cProvided by publisher.
520			_a"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- _cProvided by publisher.
610	2	0	_aTheranos (Firm) _xHistory.
650		0	_aHematologic equipment industry _zUnited States.
650		0	_aFraud _zUnited States.
906			_a7 _bcbc _corigcop _d2 _encip _f20 _gy-gencatlg
942			_2lcc _cBK